We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma. Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, dual-action AR-13324 and triple-action PG324, are once-daily eye drops that, if approved, will provide eye-care professionals with the first novel intraocular pressure-lowering mechanisms of action, or MOA, to treat glaucoma in nearly 20 years.
Jul 24, 2014
Aerie Pharmaceuticals, Inc. Receives Health Canada "No Objection Letter" to Commence Phase 3 Registration Trial of RhopressaTM in Patients with Glaucoma in Canada
Jul 23, 2014
Aerie Pharmaceuticals to Announce Second Quarter 2014 Financial Results and Host Conference Call on Wednesday, August 6, 2014
View all »Events & Presentations
Aug 6, 2014 at 5:00 PM ET
Aerie Pharmaceuticals, Inc. Second Quarter 2014 Earnings Call